AK-001

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAK-001
Drug Alias NameAK-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionSialic acid-binding Ig-like lectin 8 inhibitorsImmunomodulators
TargetsSialic acid-binding Ig-like lectin 8
Therapy Area/IndicationsCommunity Acquired PneumoniaHypersensitivityNasal Polyps +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAllakos Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Rundekang Medical Tech Co Ltd
Inactive CompaniesAllakos Inc
Active IndicationsCommunity Acquired Pneumonia
Inactive IndicationsHypersensitivityNasal PolypsUrinary Tract Infections +[4] 

Other Information

ATC CodeN/A
Related LinksN/A